The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

被引:38
|
作者
Goette, Matthias [1 ,2 ,3 ]
机构
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada
[3] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada
基金
加拿大健康研究院;
关键词
HIV-1; REVERSE-TRANSCRIPTASE; CROSS-RESISTANCE; MUTATIONAL BIAS; NS5A INHIBITOR; VIRUS; PROTEASE; FIDELITY; REPLICATION; INFECTION; VARIANTS;
D O I
10.1016/j.coviro.2012.08.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The selection of resistance to antiviral drugs depends on multiple parameters, including the genetic barrier that is often broadly defined as the number of mutations required to overcome drug selective pressure. In this review, it is intended to assess the roles of genetic barrier and viral fitness at various stages of the selection process. Several examples in the fields of HIV and HCV drug resistance show that the two parameters are distinct and independent. An analogy to the concept of kinetic versus thermodynamic control of chemical reactions supports a more narrow definition of the genetic barrier as the kinetic obstacle for the generation of genetic changes required to overcome selective pressure.
引用
收藏
页码:644 / 650
页数:7
相关论文
共 50 条
  • [21] Advances in antiviral drug discovery and development: Part II: Advancements in antiviral drug development
    Saxena, Shailendra K.
    Mishra, Niraj
    Saxena, Rakhi
    FUTURE VIROLOGY, 2009, 4 (03) : 209 - 215
  • [22] Antiviral drug resistance - Use the right antiviral drug and hit the virus hard
    Pillay, D
    Geddes, AM
    BRITISH MEDICAL JOURNAL, 1996, 313 (7056): : 503 - 504
  • [23] Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
    Kristof Theys
    Koen Deforche
    Gertjan Beheydt
    Yves Moreau
    Kristel van Laethem
    Philippe Lemey
    Ricardo J Camacho
    Soo-Yon Rhee
    Robert W Shafer
    Eric Van Wijngaerden
    Anne-Mieke Vandamme
    BMC Bioinformatics, 11
  • [24] Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
    Theys, Kristof
    Deforche, Koen
    Beheydt, Gertjan
    Moreau, Yves
    van Laethem, Kristel
    Lemey, Philippe
    Camacho, Ricardo J.
    Rhee, Soo-Yon
    Shafer, Robert W.
    Van Wijngaerden, Eric
    Vandamme, Anne-Mieke
    BMC BIOINFORMATICS, 2010, 11
  • [25] ASSAYS FOR ANTIVIRAL DRUG-RESISTANCE
    KIMBERLIN, DW
    SPECTOR, SA
    HILL, EL
    BIRON, KK
    HAY, AJ
    MAYERS, DL
    WHITLEY, RJ
    ANTIVIRAL RESEARCH, 1995, 26 (04) : 403 - 413
  • [26] Antiviral Drug Resistance of Human Cytomegalovirus
    Lurain, Nell S.
    Chou, Sunwen
    CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (04) : 689 - 712
  • [27] Computational coevolution of antiviral drug resistance
    Rosin, CD
    Belew, RK
    Morris, GM
    Olson, AJ
    Goodsell, DS
    ARTIFICIAL LIFE, 1998, 4 (01) : 41 - 59
  • [28] DRUG-RESISTANCE AND ANTIVIRAL AGENTS
    MCGILL, J
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1977, 3 (03) : 284 - 285
  • [29] Antiviral drug resistance as an adaptive process
    Irwin, Kristen K.
    Renzette, Nicholas
    Kowalik, Timothy F.
    Jensen, Jeffrey D.
    VIRUS EVOLUTION, 2016, 2 (01)
  • [30] Computational coevolution of antiviral drug resistance
    Rosin, CD
    Belew, RK
    Morris, GM
    Olson, AJ
    Goodsell, DS
    ARTIFICIAL LIFE VI, 1998, : 81 - 90